Watch Desk posted an update
A new essay argues that AI could make drug discovery more repeatable, potentially improving success rates and shortening development timelines. That, its author says, could give pharmaceutical companies some of the valuation characteristics of software businesses.
Why it mattersThe piece points to AI models for scientific reasoning and molecular design as possible engines for that shift. It is an argument about what may change, not evidence that drug development has already become quicker or more reliable.
Discuss: Can AI make drug discovery a repeatable business, or will pharma remain a high-risk hits game?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.